In March 2017, a new law came into force in Germany that also promises relief for people with Crohn’s disease – cannabis has since been available as a medicine, as a prescription . For Crohn’s disease patients, there has been hope since then that their suffering would be alleviated. Like all others who receive cannabis by prescription, Crohn’s disease patients must also participate in a scientific companion survey. But can so-called medicine cannabis actually alleviate the symptoms of Crohn’s disease? After more than two years, where these studies are now continuing, one can draw a first conclusion, even if cannabis on prescription can actually relieve the symptoms of Crohn’s disease.
Cannabis relieves symptoms
Some Crohn’s sufferers actually seem to benefit from the treatment. This is shown by studies in Germany. But the studies are not clear enough to say that cannabis really helps on prescription for Crohn’s disease. Drawing on other studies from other countries will make it even clearer. For example, a study conducted in Israel shows that cannabinoids do not improve intestinal inflammation. The symptoms are significantly reduced . In this way, improved cannabis by prescription in some way, the quality of life of those affected. First of all, according to a study, cannabinoids alleviate diarrheal symptoms. It is assumed that the cannabinoids activate the CB1 receptors in the gastrointestinal tract. This has an anti-inflammatory effect. That does not sound bad. It has to be said that the studies are still in their infancy. But the results so far give reason for hope.
Studies not clear
Of course, many people affected by Crohn’s disease are waiting for such studies before they even turn to medical cannabis. The shyness of taking cannabis by prescription is very great, especially in Germany. But this cannabis has no intoxicating effect and does not make you dependent . Even more than two and a half years after the legal introduction of medical cannabis, the number of prescribing cannabinoids is still manageable. The number of participants in the studies that are linked to this is correspondingly limited. A major obstacle to prescribing many cannabis is that, for most applications, there is still no comprehensive risk and benefit assessment available. This also applies to Crohn’s disease. This fact also makes it difficult to make scientifically based statements about the use of cannabis on prescription.